patent.fyi
Applications  /  US 2026/0354386
United States Patent Application Publication

US 2026/0354386 A1

Published
Nov 12, 2026
Filed
May 31, 2024
Earliest date on the face
May 31, 2023
Classification
A01N 63/50
First published here
Nov 18, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Replace the toxin core

What ifWhat if a fermentation-derived small-molecule insecticide supplied the insecticidal activity?
Claim language“domain I (DI), domain II (DII), and domain III (DIII)”

A water-dispersible formulation deposits a spinosyn on foliage. Feeding larvae ingest the residue, and the active compound disrupts nicotinic acetylcholine receptor signaling in susceptible insects.

1.1Supply the active core

What ifWhat if the formulation delivered an active Cry1 core directly?
Claim language“a protease cleavage site”

A truncated Cry1 polypeptide supplies the active core without a designed junction for releasing it from a protoxin segment. After ingestion, the core acts on the midgut epithelium of susceptible larvae.

1.1Separate the two proteins

What ifWhat if the Cry1 protein and the binding protein occupied separate particles in the same formulation?
Claim language“a linker peptide”

Two populations of water-dispersible particles carry the proteins separately and release them after ingestion. The Cry1 protein acts independently in susceptible larvae, and the binding protein binds its target independently.

1.1Direct exposure by placement

What ifWhat if placement on feeding surfaces directed exposure to the pest?
Claim language“a nanobody”

A directed spray deposits Cry1 on the plant surfaces where susceptible larvae feed. The larvae ingest the residue, and the Cry1 core interacts with receptors in their midgut.

1.1Protect with a particle matrix

What ifWhat if a water-dispersible particle matrix carried the Cry1 core?
Claim language“a C-terminal segment of a Cry1 protoxin domain”

The Cry1 core is entrapped in a starch-based matrix that forms particles for application to foliage. The particles carry the protein in the dried deposit and release it as the matrix hydrates and breaks down after ingestion.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Magnetic model for classroom instruction

A tabletop model uses eight colored blocks to represent the three Cry1 domains, the cleavage site, the two protoxin segments, the linker, and the nanobody. Recessed magnets connect the blocks in the stated N-terminal to C-terminal order, and a flexible strap represents the linker. A removable pin at the cleavage-site block lets students separate the three-domain portion from the rest of the model.

Component substitution

Flexible hinge in a display model

A silicone living hinge replaces a rigid connector in a physical model of the linker peptide. One end of the hinge attaches to the block representing the N-terminal protoxin segment, and the other attaches to the block representing the nanobody. The hinge bends as the nanobody block rotates, while the block representing the C-terminal protoxin segment stays attached to it.

Parameter or scale variation

Two scales for a topology display

A printed schematic comes in a 24-centimeter bench format and a 120-centimeter wall format. Both versions divide the strip into eight equal-width slots and place the labeled components in the stated N-terminal to C-terminal order. The slots measure 3 centimeters on the bench version and 15 centimeters on the wall version, and the cleavage marker sits in the fourth slot on both.

Combination with existing systems

Topology display linked to inventory records

A laboratory inventory system stores a read-only diagram of the eight components alongside each reference record. The diagram stores one ordinal and one display label per component, and a renderer arranges the components from left to right by ordinal. The inventory record links to the diagram through a stable identifier so users retrieve the same view from the catalog or a sample record.

Automated or data-driven variant

Automatic checks for diagram component order

A script reads a table with one row per diagram component and columns for label and ordinal. It sorts the rows by ordinal and compares the resulting label list with the eight labels in the reference arrangement. It reports missing or duplicate ordinals and identifies the first position where the labels differ.

Sensor feedback for a tabletop model

Eight labeled blocks carry passive identification tags, and a tabletop rail has one short-range reader beneath each slot. A controller polls the slots from the N-terminal end to the C-terminal end and maps each tag to a component label. An indicator beside each slot lights when its block matches the stored reference position.

Specific version of a part

Flexible peptide spacer

A short glycine- and serine-rich peptide sits between the N-terminal protoxin segment and the binding domain. The spacer provides conformational flexibility at the junction.

Trypsin sensitive cleavage site

A trypsin-sensitive peptide junction sits between domain III and the N-terminal protoxin segment. A compatible gut protease cleaves the exposed junction after ingestion.

Single variable binding domain

A single antibody variable domain occupies the position between the peptide linker and the C-terminal protoxin segment. Loops on the variable domain contact the target.

Continuous peptide backbone

A single open reading frame encodes the components in their specified order. Translation produces one continuous polypeptide with peptide bonds at the component junctions.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2014/0148390 A1
Published
May 29, 2014
Filed
Jul 4, 2012
Class
C07K 14/64
Document BUS 2016/0326562 A1
Published
Nov 10, 2016
Filed
Dec 10, 2014
Class
C12P 21/005
Claim 1
Document A
Document B
1.1from N-terminus to C-terminus, polypeptides comprising domain I (DI), domain II (DII), and domain III (DIII) of a Cry1 protein, a protease cleavage site, an N-terminal segment of a Cry1 protoxin domain, a linker peptide, a nanobody, and a C-terminal segment of a Cry1 protoxin domain
One embodiment of the invention is a fusion polypeptide comprising Relaxin, a linker peptide comprising an endo-protease cleavage site and a proteinaceous half-life extending moiety, wherein the linker peptide connects Relaxin with the half-life extending moiety.
A · US 2014/0148390 A1 · ¶ 11
1.2wherein said polypeptides are operably linked.
Typically, a fusion protein is expressed from a fusion gene in which a nucleotide sequence encoding a polypeptide sequence from one protein is appended in frame with, and optionally separated by a linker or stretcher from, a nucleotide sequence encoding a polypeptide sequence from a different protein. The fusion gene can then be expressed by a recombinant host cell as a single protein.
A · US 2014/0148390 A1 · ¶ 27
It has been found that only BDNF-antibody-fusion-formats are expressed and properly assembled in biologically active form in complex with a second not-fused BDNF polypeptide if the format comprises exactly one BDNF polypeptide fused covalently via a linker peptide to an antibody fragment and exactly one not-fused BDNF polypeptide.
B · US 2016/0326562 A1 · ¶ 202

An empty cell means only that no passage was reproduced there.

Statements in these documents
(2010)) Due to the limited in-vivo half life of Relaxin, treatment of patients has to be repeated every 14 to 21 days, whereby compound administration has to be performed as a continuous infusion for at least 48 hours.
A · US 2014/0148390 A1 · ¶ 5
Therefore, the invention provides Relaxin fusion polypeptides with extended half-life whereby the fusion protein by itself serves as a depot for release of the biologically active Relaxin.
A · US 2014/0148390 A1 · ¶ 1
However, some fusion polypeptides, especially complex fusion polypeptides, polypeptides with low solubility or folding difficulties, as well as polypeptides interacting with the cell expressing it are often obtained at very low yields.
B · US 2016/0326562 A1 · ¶ 2
The improvement can be e.g. an increased yield, a more robust production process, a more simple process, and/or a reduced complexity during downstream processing.
B · US 2016/0326562 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0354386 A1, claim 1, first published 2026-11-18T22:28:45-05:00, https://patent.fyi/US20260354386/, SHA-256 751b37077c5c8bb1d16b5625a9b546fdac0f19d6c00a38c5340d6bb9e987acfa
First published
Permanent addresshttps://patent.fyi/US20260354386/
Content fingerprint (SHA-256)751b37077c5c8bb1d16b5625a9b546fdac0f19d6c00a38c5340d6bb9e987acfa
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi